NORTH CHICAGO, Ill., Feb. 15, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.
The cash dividend is payable May 15, 2024, to stockholders of record at the close of business on April 15, 2024.
Since the company's inception in 2013, AbbVie has increased its dividend by more than 285 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas ? immunology, oncology, neuroscience, and eye care ? and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter), and YouTube.
Chamlion, a gamechanging force in the digitalization of dentistry, is set to captivate attendees at the International Dental Equipment Exhibition (IDEX) 2024 in Turkey. With a comprehensive display of integrated dental 3D printing solutions,...
Dr. Clauder's has joined forces with protein pioneer Calysta to launch the world's first dog treats made with FeedKind® Pet protein, a revolutionary new pet food ingredient.
Announced at the world's leading pet trade fair, Interzoo, the...
Chipotle Mexican Grill UK, the fast-casual restaurant chain that serves burritos, bowls, tacos, quesadillas, and salads made with real ingredients, is celebrating International Nurses Day with a BUY-ONE-GET-ONE-FREE (BOGOF) on all entrees for NHS...
Starting 2024 with a positive EBITDA
Q1 2024 highlights
Total net revenues of SEK 139.3 m (158.8)EBITDA of SEK 15.9 m (-41.1)Net earnings of SEK -8.9 m (-63.9)US Commercial segment net revenues of SEK 129.3 m (140.3), in local currency USD 12.4 m...
Today scientists from Colossal Biosciences, the world's first de-extinction company, and the University of Melbourne announce a major step forward in the effort to save Australia's endangered northern quoll (Dasyurus hallucatus) from the invasive...
